MedPath

A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.

Recruiting
Conditions
Deterioration, Clinical
Pulmonary Embolism and Thrombosis
Registration Number
NCT05098769
Lead Sponsor
Shengjing Hospital
Brief Summary

This study collected clinical, laboratory, and CT parameters of acute patients with acute pulmonary embolism from admission to predict adverse outcomes within 30 days after admission into hospital.

Detailed Description

This study collected clinical, laboratory, and CT parameters of acute patients with acute pulmonary embolism from admission. The outcomes of interest were defined as the occurrence of adverse outcomes within 30 days after admission into hospital.

Eligible patients were randomized in some ratio into derivation and validation cohorts. The derivation cohort was used to develop and evaluate a multivariable logistic regression model for predicting the outcomes of interest. The discriminatory power was evaluated by comparing the nomogram to the established risk stratification systems. The consistency of the nomogram was evaluated using the validation cohort.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography
Exclusion Criteria
  • pregnancy
  • reception of reperfusion treatment before admission
  • missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Adverse outcomes30 days

The outcomes of interest were defined as the occurrence of adverse outcomes within 30 days after admission. Adverse outcomes were defined as PE-related deaths, the need for mechanical ventilation, the need for cardiopulmonary resuscitation, and the need for life-saving vasopressor and reperfusion treatment.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Shenjing Hospital of CHINA MEDICAL UNIVERSITY

🇨🇳

Shenyang, Liaoning, China

© Copyright 2025. All Rights Reserved by MedPath